Swedish biotech firm gets green light to take diabetes candidate to clinical phase

Atrogi is starting clinical studies of its type 2 diabetes candidate, ATR-258, in Germany.
Atrogi CEO Alexandra Ekman Ryding | Photo: Atrogi /PR
Atrogi CEO Alexandra Ekman Ryding | Photo: Atrogi /PR
by christian bundgaard, translated by catherine brett

Atrogi, a biotech firm based in Sweden, is entering the clinical phase with its new class of molecules for the treatment of type 2 diabetes.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading